Bayer: Atrial Fibrillation trials

The registry lists 64 Atrial Fibrillation studies with Bayer as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 3Phase 2 6Phase 3 4No phase 51(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial FibrillationRecruitingNCT07625215Phase 2
• A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for StrokeTerminatedNCT05643573Phase 3Results posted
• Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.CompletedNCT04218266Phase 2Results posted
• Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for CardioversionCompletedNCT01674647Phase 3Results posted
• Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial FibrillationCompletedNCT00494871Phase 3Results posted
• An Observational Study (Called RETAF-PS) Using a Patient Survey to Learn More About Treatment Outcomes in Patients With Irregular and Often Rapid Heartbeat (Atrial Fibrillation) Treated With Apixaban in a Real World SettingCompletedNCT05471830
• A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver FunctionCompletedNCT05419635Phase 1
• A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.CompletedNCT04722679
• A Study Using Electronic Health Information to Learn About Rivaroxaban Compared to Warfarin in Participants With Non-valvular Atrial Fibrillation (NVAF) and DiabetesCompletedNCT04509193
• Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K AntagonistsCompletedNCT04297072
• Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)CompletedNCT04249401
• Survey on Belgian Patients Suffering From Irregular Heartbeat and Starting Treatment With a Drug to Prevent Blood Clots in Blood Vessels and the Heart. This Study is Also Called BELANCOS.CompletedNCT04183270
• Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban TreatmentCompletedNCT04174859
• Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary CareCompletedNCT04099238
• Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical PracticeCompletedNCT03847181
• A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.TerminatedNCT03715725
• Study to Develop a Tool to Estimate the Kidney Function in Databases Without Laboratory DataCompletedNCT03605810
• Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. PhenprocoumonCompletedNCT03563937
• Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian DatabasesCompletedNCT03474757
• Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists EventsCompletedNCT03462446
• Rivaroxaban vs Warfarin for SPAF in Multi-morbid PatientsCompletedNCT03374540
• Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal DysfunctionCompletedNCT03359876
• Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in SwedenCompletedNCT03311139
• Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial FibrillationCompletedNCT03284762
• Real-world Dosing Patterns of Rivaroxaban in the United StatesCompletedNCT03242278
• Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With RivaroxabanCompletedNCT02975453
• Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k AntagonistsCompletedNCT02960880
• Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision AlgorithmWithdrawnNCT02900404
• Xarelto Evidence in Real Life of Patients' Preference and Satisfaction StudyCompletedNCT02876718
• A Digital Non-interventional Atrial Fibrillation (AF) Screening Study With Commercial Pulse Detection SystemsCompletedNCT02875106
• Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in FranceCompletedNCT02864758
• Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional StudyCompletedNCT02784717
• Real-world Comparative Effectiveness of Rivaroxaban Versus VKACompletedNCT02690155
• Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K AntagonistCompletedNCT02687867
• Real-world Comparative Effectiveness of Apixaban Versus Vitamin K AntagonistCompletedNCT02687854
• Burden of Illness in Atrial FibrillationCompletedNCT02615587
• Atrial Fibrillation Patient Preference StudyCompletedNCT02611635
• Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control StrategiesCompletedNCT02610153
• Anticoagulation Preference by AF Patients StudyCompletedNCT02607371
• A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With HypertensionCompletedNCT02585076
• An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care CentersCompletedNCT02559232
• Bioequivalence Study of RivaroxabanCompletedNCT02537457Phase 1
• Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male SubjectsCompletedNCT02537405Phase 1
• Atrial Fibrillation Screening With a Smartphone Device and iECG ApplicationWithdrawnNCT02534532
• Real-Life Evidence on Stroke Prevention in SPAFCompletedNCT02485873
• An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care CentresCompletedNCT02470767
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)CompletedNCT02468102
• Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of SpainCompletedNCT02262676
• BAY 59-7939 (Xarelto, SPAF), Non Interventional StudiesCompletedNCT02090543
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)CompletedNCT01947998
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)CompletedNCT01947985
• Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)CompletedNCT01947959
• Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant TherapyCompletedNCT01928979
• Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic EmbolismCompletedNCT01855139
• Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial FlutterCompletedNCT01839357Phase 3
• Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) IndicationCompletedNCT01805531
• Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA RegionCompletedNCT01800006
• Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in AsiaCompletedNCT01750788
• Xarelto for Prevention of Stroke in Patients With Atrial FibrillationCompletedNCT01606995
• Xarelto [SPAF-QOL] Post-marketing Surveillance in JapanCompletedNCT01598051
• BAY59-7939 Japanese in Atrial Fibrillation (2nd)CompletedNCT00973323Phase 2
• BAY59-7939 in Atrial Fibrillation Once Daily (OD)CompletedNCT00973245Phase 2
• BAY59-7939, Japanese Phase II in Atrial FibrillationTrial StatusCompletedNCT00779064Phase 2
• Study to Investigate the Effect of the A1 Agonist Capadenoson on Ventricular HR in Patients With Persistent or Permanent Atrial Fibrillation.CompletedNCT00568945Phase 2